World Alzheimer's Report 2022 highlights Cognitive Stimulation Therapy

Report this content

Copenhagen, Denmark, October 7, 2022 – Brain+ A/S (Nasdaq First North: BRAINP)

The recently published World Alzheimer Report 2022 (21. September 2022) highlights Cognitive Stimulation Therapy (CST), the therapy form that Brain+ is digitalizing with global experts, as a cost-effective evidence-based therapy for people with mild-to-moderate dementia that should be researched and implemented globally.

The World Alzheimer Report 2022 is a research and policy document released by the global Alzheimer’s interest organization, Alzheimer’s Disease International (ADI). The 2022 report is dedicated to the vast topic of post-diagnosis support.

Key recommendation

“Nonpharmacological interventions, such as Cognitive Stimulation Therapy (CST) and Cognitive Rehabilitation, should be further researched and implemented as possible cost-effective and impactful interventions globally.” (World Alzheimer’s Report 2022, recommendations)

Global potential for Cognitive Stimulation Therapy products

  • While 45% of people being diagnosed with dementia globally are not offered any type of support, an average of 30% are offered some form of Cognitive Stimulation, speaking to the global potential of the Brain+ CST product line.
  • Cognitive stimulation therapy has been shown to have benefits equivalent to the use of cholinesterase inhibitors (the current pharmacological standard of care), cognitive rehabilitation, exercise, occupational therapy, and speech therapy. At the same time, it is relatively cost-effective, as no specialized medical equipment or skillset is required.

Brain+ is pioneering the development of CST as digital therapeutics

Brain+ began work with CST experts and key opinion leaders around 5 years ago, to create digitalized delivery of CST, with the aim to make CST a scalable digital therapeutic solution. In 2022 the first CST product, CST-Therapist Companion, will be launched on the Danish market, and in Q2 2023 in the German market.

CST is a cost-effective treatment

It has been found that cognitive stimulation therapy is more cost-effective than usual care, with a recent economic analysis finding that offering CST to every new case of dementia in England would still be cost-effective. This speaks to the potential for digitalized CST as a reimbursable digital therapeutic, as the health economics are favorable for this therapy.

Post-diagnostic care is a large unmet clinical need in both high- and low-income countries

(Excerpt from World Alzheimer’s Report 2022) “A surprising number of people living with dementia indicated they had not been offered post-diagnosis support beyond the initial information provided immediately after their diagnosis. In lower-income countries, 45% indicated they had not been offered support, while in higher-income countries, 37% indicated they were offered nothing. 62% of informal carers from lower-income countries said that the person in their care had not been given access to post-diagnosis support, whereas in higher-income countries 36% indicated they had not. 64% of respondents living with dementia indicated they did not have a personalized care plan – a roadmap indicating how they would want to receive care throughout the progression of their condition”

World Alzheimer’s Report 2022

See Page 245, for the article on Cognitive Stimulation Therapy.

Cognitive Stimulation Therapy (CST)

Cognitive Stimulation Therapy (CST) is a manualized psychosocial group intervention for people living with mild-to-moderate dementia aimed at improving cognitive function through themed group activities that implicitly stimulate skills. No specialist equipment or medical knowledge is required, it is culturally adaptable, and (relatively) low-cost.